Safety and Efficacy Study of Angiotech Central Venous Catheter to Prevent Bacterial Catheter Colonization

PHASE3CompletedINTERVENTIONAL
Enrollment

960

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Bacterial Infections
Interventions
DEVICE

Central Venous Catheter

7-French x 20-cm, triple lumen, short-term CVC vs. 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU

Trial Locations (21)

19102

Drexel University College of Medicine, Philadelphia

19713

Christiana Care Research Institute, Newark

22601

Winchester Medical Center, Winchester

22908

University of Virginia, Department of Anesthesiology, Charlottesville

30030

Atlanta Institute for Medical Research Inc, Decatur

32605

Florida Research Network, LLC, Gainesville

35235

Cardio-Thoracic Surgeons, P.C., Birmingham

43608

St Vincent Mercy Medical Center, Bldg 1, Toledo

43614

Medical University of Ohio, Toledo

45267

Pulmonary and Critical Care Medicine, Cincinnati

57701

Rapid City Regional Hospital, Rapid City

70570

Kerry Thibodeaux, M.D., Opelousas

73104

Universty of Oklahoma HSC, Oklahoma City

80204

Denver Health Medical Center, Denver

92123

Pulmonary Center Sharp Memorial Hospital, San Diego

92868

Pulmonary Consultant Group, Orange

95119

Kaiser Permanente Santa Teresa, San Jose

98405

Franciscan Health System Research Center, Tacoma

01655

UMASS Medical School, Dept of Anesthesiology, Worcester

07112

Newark Beth Israel Hospital, Newark

02903

Rhode Island Hospital, Providence

Sponsors
All Listed Sponsors
lead

Angiotech Pharmaceuticals

INDUSTRY

NCT00288418 - Safety and Efficacy Study of Angiotech Central Venous Catheter to Prevent Bacterial Catheter Colonization | Biotech Hunter | Biotech Hunter